U.S. Markets open in 37 mins

Free Stock Performance Review on Zoetis and Three Additional Generic Drugs Stocks

Stock Research Monitor: FLXN, MNTA, and PETQ

LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ZTS sign up now at www.wallstequities.com/registration. WallStEquities.com shifts focus on the Generic Drugs industry, which is not only armed to survive battles over patents, but also to adopt licensing and partnering strategies to launch new products successfully and ensure that their market thrives. Under evaluation this morning are these four stocks: Flexion Therapeutics Inc. (NASDAQ: FLXN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), PetIQ Inc. (NASDAQ: PETQ), and Zoetis Inc. (NYSE: ZTS). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Flexion Therapeutics

Burlington, Massachusetts headquartered Flexion Therapeutics Inc.'s stock finished Monday's session 1.02% higher at $26.76 with a total trading volume of 210,892 shares. Over the last month and the previous three months, the Company's shares have advanced 0.45% and 14.07%, respectively. Additionally, the stock has gained 55.58% over the past year. The stock is trading above their 50-day and 200-day moving averages by 2.95% and 7.82%, respectively. Moreover, shares of Flexion Therapeutics, which focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions, have a Relative Strength Index (RSI) of 52.24.

On June 01st, 2018, Flexion Therapeutics announced a grant of inducement stock options to eight new employees for an aggregate of 50,000 shares of common stock. The Compensation Committee of the Board of Directors approved the grants, with an effective date of June 01st, 2018. The stock options have an exercise price of $27.01 per share and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). Get the full research report on FLXN for free by clicking below at:

www.wallstequities.com/registration/?symbol=FLXN


Momenta Pharmaceuticals

Shares in Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc. rose 2.74%, ending yesterday's session at $22.50 with a total trading volume of 487,194 shares. The stock has gained 23.29% in the previous three months and 35.14% over the past year. The Company's shares are trading 3.45% above their 50-day moving average and 31.99% above their 200-day moving average. Moreover, share of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the US, have an RSI of 45.94. Find your free research report on MNTA at:


www.wallstequities.com/registration/?symbol=MNTA


PetIQ

On Monday, Eagle, Idaho headquartered PetIQ Inc.'s stock declined slightly by 0.70%, to close the day at $22.66. A total volume of 513,504 shares was traded, which was above their three months average volume of 421,410 shares. The Company's shares have advanced 24.16% in the last month. The stock is trading 8.76% above its 50-day moving average. Additionally, shares of PetIQ, which develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the US, Canada, and Europe, have an RSI of 65.35.

On June 06th, 2018, PetIQ announced that management will participate in the Jefferies 2018 Consumer Conference in Nantucket, Massachusetts. The presentation will be on June 20th, 2018, at 10:00 a.m. ET. It can be accessed live under the "Investors" section of the Company's website. Sign up today for the free research report on PETQ at:

www.wallstequities.com/registration/?symbol=PETQ

Zoetis

Shares in Parsippany, New Jersey headquartered Zoetis Inc. ended the day 0.30% lower at $88.93. A total volume of 3.52 million shares was traded, which was above their three months average volume of 2.44 million shares. The stock has gained 7.21% in the last month, 6.95% in the previous three months, and 42.17% over the past year. The Company's shares are trading above their 50-day and 200-day moving averages by 5.51% and 17.89%, respectively. Furthermore, shares of Zoetis, which discovers, develops, manufactures, and markets veterinary vaccines and medicines in the US and internationally, have an RSI of 67.68. Wall St. Equities' research coverage also includes the downloadable free report on ZTS at:

www.wallstequities.com/registration/?symbol=ZTS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities